| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_471357c16fd4ce68bc752c8a4eb208cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbbe4ed80d4c19b9f1b8fa19a35aba39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb77689c3aedb2fe6079ca636b214992
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_959a84e534503cbc773d31f14a028bc8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate |
2016-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06ddf37726860b74c506a2b18f05122b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7940c5ca7a6de2170065eb8efbc86909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_385b5161674377589687a27d49f40c07 |
| publicationDate |
2021-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11007230-B1 |
| titleOfInvention |
Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders |
| abstract |
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. Increasing evidence shows autoimmune mechanisms likely promote disease progression. Human umbilical cord blood (hUCB) derived plasma is rich in cytokines and growth factors that are required for growth and survival of cells during hematopoiesis. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. |
| priorityDate |
2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |